Hypnion Inc. aims to develop the next generation of drugs for the multi-billion dollar sleep market. It is taking marketed CNS drugs that have known sleep/wake side effects, then optimizing those effects to create safe, non-addictive patentable analogs.
Five-Biotech
381 Plantation Street
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.
Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.
Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.
